Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04748055 · ClinicalTrials.gov registry record
Examining Changes in Nasal IL-1 During Acute Asthma Exacerbation in Adolescents
A clinical trial, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- 40
- Enrollment target
NCT04748055 is a clinical trial that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 40 participants.
The verdict
NCT04748055 has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- 40 participants
- Enrollment target
Study Summary
To study the change from baseline in IL-1β (interleukin 1 beta) concentrations in the nasal airway during acute asthma exacerbation, specifically to measure the degree of change and identify the timing of peak IL-1β concentration. This information will allow the investigators to estimate effect size and guide decisions about the optimal timing of anakinra administration for the future study.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2021-07-27 |
| Est. Completion | 2024-02-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04748055
The ClinicalTrials.gov registry entry for NCT04748055 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT04748055 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04748055 about?
NCT04748055 is a clinical study titled "Examining Changes in Nasal IL-1 During Acute Asthma Exacerbation in Adolescents". To study the change from baseline in IL-1β (interleukin 1 beta) concentrations in the nasal airway during acute asthma exacerbation, specifically to measure the degree of change and identify the timing of peak IL-1β concentration. This information will allow the investigators to estimate effect size...
What is the current status of trial NCT04748055?
This trial is currently completed. The enrollment target is 40 participants. The study started on 2021-07-27. Estimated completion is 2024-02-08.
Who is sponsoring clinical trial NCT04748055?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.